Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지
DOI QR코드

DOI QR Code

Long-term Surgical Outcomes in Oligometastatic Non-small Cell Lung Cancer: A Single-Center Study

  • Seungmo Yoo (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Won Chul Cho (Department of Thoracic and Cardiovascular Surgery, Gangneung Asan Hospital, University of Ulsan College of Medicine) ;
  • Geun Dong Lee (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Sehoon Choi (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Hyeong Ryul Kim (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Yong-Hee Kim (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Dong Kwan Kim (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Seung-Il Park (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Jae Kwang Yun (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2022.09.14
  • Accepted : 2022.11.06
  • Published : 2023.01.05
Download PDF
⟨ Previous Next ⟩

Abstract

Background: We reviewed the clinical outcomes of patients with oligometastatic (OM) non-small cell lung cancer (NSCLC) who received multimodal therapy including lung surgery. Methods: We retrospectively analyzed 117 patients with OM NSCLC who underwent complete resection of the primary tumor from 2014 to 2017. Results: The median follow-up duration was 2.91 years (95% confidence interval, 1.48-5.84 years). The patients included 73 men (62.4%), and 76 patients (64.9%) were under the age of 65 years. Based on histology, 97 adenocarcinomas and 14 squamous cell carcinomas were included. Biomarker analysis revealed that 53 patients tested positive for epidermal growth factor receptor, anaplastic lymphoma kinase, or ROS1 mutations, while 36 patients tested negative. Metastases were detected in the brain in 74 patients, the adrenal glands in 12 patients, bone in 5 patients, vertebrae in 4 patients, and other locations in 12 patients. Radiation therapy for organ metastasis was performed in 81 patients and surgical resection in 27 patients. The 1-year overall survival (OS) rate in these patients was 82.8%, and the 3- and 5-year OS rates were 52.6% and 37.2%, respectively. Patients with positive biomarker test results had 1-, 3-, and 5-year OS rates of 98%, 64%, and 42.7%, respectively. These patients had better OS than those with negative biomarker test results (p=0.031). Patients aged ≤65 years and those with pT1-2 cancers also showed better survival (both p=0.008). Conclusion: Surgical resection of primary lung cancer is a viable treatment option for selected patients with OM NSCLC in the context of multimodal therapy.

Keywords

References

  1. Hong S, Won YJ, Park YR, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat 2020;52:335-50. https://doi.org/10.4143/crt.2020.206 
  2. Pereira JL, Gomes M, Teixeira AL, Coelho A, Rolfo C, Araujo A. Potential and importance of metalloproteinases and interleukins in inflammation and metastasization in non-small cell lung cancer. Transl Cancer Res 2018;7:782-95. https://doi.org/10.21037/tcr.2018.05.16 
  3. Socinski MA, Crowell R, Hensing TE, et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132(3 Suppl):277S-289S. https://doi.org/10.1378/chest.07-1381 
  4. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst Rev 2010;(5):CD007309. https://doi.org/10.1002/14651858.CD007309.pub2 
  5. Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015;16:141-51. https://doi.org/10.1016/S1470-2045(14)71173-8 
  6. Parikh RB, Cronin AM, Kozono DE, et al. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2014;89:880-7. https://doi.org/10.1016/j.ijrobp.2014.04.007 
  7. Congedo MT, Cesario A, Lococo F, et al. Surgery for oligometastatic non-small cell lung cancer: long-term results from a single center experience. J Thorac Cardiovasc Surg 2012;144:444-52. https://doi.org/10.1016/j.jtcvs.2012.05.051 
  8. Hanagiri T, Takenaka M, Oka S, et al. Results of a surgical resection for patients with stage IV non--small-cell lung cancer. Clin Lung Cancer 2012;13:220-4. https://doi.org/10.1016/j.cllc.2011.05.006 
  9. Endo C, Hasumi T, Matsumura Y, et al. A prospective study of surgical procedures for patients with oligometastatic non-small cell lung cancer. Ann Thorac Surg 2014;98:258-64. https://doi.org/10.1016/j.athoracsur.2014.01.052 
  10. Johnson KK, Rosen JE, Salazar MC, Boffa DJ. Outcomes of a highly selective surgical approach to oligometastatic lung cancer. Ann Thorac Surg 2016;102:1166-71. https://doi.org/10.1016/j.athoracsur.2016.04.086 
  11. He J, Li Y, An J, Hu L, Zhang J. Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis. World J Surg Oncol 2017;15:36. https://doi.org/10.1186/s12957-017-1105-8 
  12. Wang Z, Gao SG, Xue Q, et al. Surgery of primary non-small cell lung cancer with oligometastasis: analysis of 172 cases. J Thorac Dis 2018;10:6540-6. https://doi.org/10.21037/jtd.2018.11.125 
  13. Zhang C, Wang L, Li W, et al. Surgical outcomes of stage IV non-small cell lung cancer: a single-center experience. J Thorac Dis 2019;11:5463-73. https://doi.org/10.21037/jtd.2019.11.30 
  14. Casiraghi M, Bertolaccini L, Sedda G, et al. Lung cancer surgery in oligometastatic patients: outcome and survival. Eur J Cardiothorac Surg 2020;57:1173-80. https://doi.org/10.1093/ejcts/ezaa005 
  15. Euhus CJ, Ripley TR, Medina CG. The role of surgery for oligometastatic non-small cell lung cancer. Cancers (Basel) 2022;14:2524. https://doi.org/10.3390/cancers14102524 
  16. Ozkaya S, Findik S, Dirican A, Atici AG. Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine. Exp Ther Med 2012;4:1035-8. https://doi.org/10.3892/etm.2012.714 
  17. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205-13. https://doi.org/10.1097/01.sla.0000133083.54934.ae 
  18. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995;13:8-10. https://doi.org/10.1200/JCO.1995.13.1.8 
  19. Reyes DK, Pienta KJ. The biology and treatment of oligometastatic cancer. Oncotarget 2015;6:8491-524. https://doi.org/10.18632/oncotarget.3455 
  20. Yang CJ, Gu L, Shah SA, et al. Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: a national analysis. Lung Cancer 2018;115:75-83. https://doi.org/10.1016/j.lungcan.2017.11.021 
  21. Ashworth A, Rodrigues G, Boldt G, Palma D. Is there an oligometastatic state in non-small cell lung cancer?: a systematic review of the literature. Lung Cancer 2013;82:197-203. https://doi.org/10.1016/j.lungcan.2013.07.026 
  22. Opitz I, Patella M, Payrard L, et al. Prognostic factors of oligometastatic non-small-cell lung cancer following radical therapy: a multicentre analysis. Eur J Cardiothorac Surg 2020;57:1166-72. https://doi.org/10.1093/ejcts/ezz384 
  23. Park BJ, Shim HS, Lee CY, et al. Genetic analysis and operative outcomes in patients with oncogene-driven advanced NSCLC treated with cytoreductive surgery as a component of local consolidative therapy. Cancers (Basel) 2021;13:2549. https://doi.org/10.3390/cancers13112549 
  24. Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther 2019;4:61. https://doi.org/10.1038/s41392-019-0099-9